Ipsen (Paris:IPN) today announces that it has executed a license agreement with PregLem SA, a biopharmaceutical company specialising in the treatment of benign gynaecological conditions and infertility. Under the terms of the agreement, Ipsen grants PregLem worldwide development and commercialisation rights to a selected range of compounds in a number of specific potential indications in the field of reproductive medicine only. The compounds include steroid sulphatase inhibitors and somatostatin antagonists, which are, for most of them, at an early stage of development. Ipsen also assigns to PregLem certain patent rights applicable in the treatment of human infertility.
